Surveillance programs have become an integral component of our understanding
of resistance. Effective surveillance programs will serve as an
early warning device to detect emerging problems, monitor changing
patterns of resistance, help guide appropriate antimicrobial therapy
based on susceptibility
data, and identify and predict gaps in the availability of existing
drugs to help industry and government target the development of
JMI Laboratories directs many surveillance programs,
including one of the world's largest, the SENTRY Antimicrobial
Surveillance Program. Greater than 30,000 unique isolates annually are sent and
processed through JMI Laboratories from its extensive network of participating
hospitals and medical centers from around the world dating back to 1997. Additional
requested surveillance studies can be created as stand-alone programs or can be
incorporated into the broader SENTRY Program platform.
here to view slides from 2006 Gordon Research Conference on New
Antibacterial Discovery & Development.
information on these topics can be found in JMI's on-line Scientific
Presentations and Bibliography. Click
here to search.